• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Rigel Pharmaceuticals, Inc. - Product Pipeline Review - Q4 2010 - Product Image

Rigel Pharmaceuticals, Inc. - Product Pipeline Review - Q4 2010

  • ID: 1446771
  • November 2010
  • 61 pages
  • Global Markets Direct

Rigel Pharmaceuticals, Inc. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Rigel Pharmaceuticals, Inc. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Rigel Pharmaceuticals, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Rigel Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including READ MORE >



List of Tables
List of Figures
Rigel Pharmaceuticals, Inc. Snapshot
Rigel Pharmaceuticals, Inc. Overview
Key Information
Key Facts
Rigel Pharmaceuticals, Inc. – Research and Development Overview
Key Therapeutic Areas
Rigel Pharmaceuticals, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Rigel Pharmaceuticals, Inc. – Pipeline Products Glance
Rigel Pharmaceuticals, Inc. Clinical Stage Pipeline Products
Phase I Products/Combination Treatment Modalities
Rigel Pharmaceuticals, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Rigel Pharmaceuticals, Inc. – Drug Profiles
R348
Product Description
Mechanism of Action
R&D Progress
R763
Product Description
Mechanism of Action
R&D Progress
ACVR2B
Product Description
Mechanism of Action
R&D Progress
Adiponectin Mimetic
Product Description
Mechanism of Action
R&D Progress
PKC Theta Inhibitor
Product Description
Mechanism of Action
R&D Progress
Rigel Pharmaceuticals, Inc. – Pipeline Analysis
Rigel Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class
Rigel Pharmaceuticals, Inc. Pipeline Products By Target
Rigel Pharmaceuticals, Inc. – Pipeline Products by Molecule Type
Rigel Pharmaceuticals, Inc. - Dormant Projects
Rigel Pharmaceuticals, Inc. – Company Statement
Rigel Pharmaceuticals, Inc. – Locations And Subsidiaries
Head Office
Recent Developments
Sep 29, 2010: Rigel Earns Milestone Payments From AstraZeneca Regarding Clinical Development Of Fostamatinib (R788)
Sep 29, 2010: Rigel Earns Milestone Payments From AstraZeneca Regarding Clinical Development Of Fostamatinib (R788)
Jan 09, 2008: Rigel Announces Initiation Of Phase 1 Clinical Trial Of R348 For Rheumatoid Arthritis, Psoriasis And Other Immune Disorders
Jan 09, 2008: Rigel Announces Initiation Of Phase 1 Clinical Trial Of R348 For Rheumatoid Arthritis, Psoriasis And Other Immune Disorders
Jan 09, 2008: Rigel Announces Initiation Of Phase 1 Clinical Trial Of R348 For Rheumatoid Arthritis, Psoriasis And Other Immune Disorders
Dec 06, 2007: Rigel Announces Initiation Of Phase 1 Clinical Trial Of R343 For Allergic Asthma By Its Partner Pfizer
Nov 09, 2007: Rigel R788 Raises Platelet Counts In Immune Thrombocytopenic Purpura (ITP) Patients In Phase 2 Study
Jul 12, 2007: Rigel Announces Start Of Phase 1 Combination Therapy Study Of R763/AS703569 In Advanced Malignancies
Apr 11, 2007: Rigel Provides Clinical Update Of R788 Phase 2 Trials In ITP, Rheumatoid Arthritis And Lymphoma
Apr 11, 2007: Rigel Provides Clinical Update Of R788 Phase 2 Trials In ITP, Rheumatoid Arthritis And Lymphoma
Financial Deals Landscape
Rigel Pharmaceuticals, Inc., Deals Volume Summary, 2004 to YTD 2010
Rigel Pharmaceuticals, Inc., Deals Summary By Region, 2004 to YTD 2010
Rigel Pharmaceuticals, Inc., Deals Summary, 2004 to YTD 2010
Rigel Pharmaceuticals, Inc. Detailed Deal Summary
Equity Offering
Rigel Pharmaceuticals Completes Public Offering Of Its Common Stock For $108 Million
Rigel Pharmaceuticals Completed the Public Offering of $135 Million
Rigel Pharmaceuticals Completes Public Offering Of $56.06 Million
Rigel Pharmaceuticals Completes Private Placement Of $15 Million
Rigel Pharmaceuticals Completes Public Offering Of $87 Million
Rigel Pharmaceuticals Completes Private Placement Of $5 Million
Rigel Pharmaceuticals Completes Private Placement Of $5 Million
Rigel Pharmaceuticals Completes Public Offering Of $63 Million
Proteros Biostructures Extends Research Agreement With Rigel Pharmaceuticals
Graffinity Pharmaceuticals Enters Into Co-Development Agreement With Rigel Pharmaceuticals
Merck Enters Into Co-Develoment Agreement With Rigel Pharmaceuticals
Licensing Agreements
Merck Serono Expands Licenisng Agreement With Rigel Pharmaceuticals
Rigel Pharmaceuticals Enters Into Licensing Agreement With Merck Serono
Rigel Pharmaceuticals Signs An Agreement With Pfizer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown

RELATED PRODUCTS